Skip to main
PEPG

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PepGen is a clinical-stage biotechnology company with a promising Enhanced Delivery Oligonucleotide platform that has shown success in delivering therapeutics to a broad range of target tissues. With the completion of recruitment in the 10mg/kg multi-dose cohort in the FREEDOM2 study of PGN-EDODM1 and the maintenance of data readout timing, PEPG is on track for a potential commercial launch in the US in FY30. Despite potential delays with the partial clinical hold, the company has a strong financial position with $132M in cash/equivalents. With encouraging drug concentrations and improved safety measures observed in preclinical studies, and the potential for emerging competitors in the field, PEPG remains a promising investment opportunity with an adjusted target of $4 per share.

Bears say

PepGen is currently facing several challenges ranging from financial constraints to complex clinical results. The company's recent 1Q26 financial results were below consensus, and their reliance on external funding to advance their drug development platform may result in delays. Additionally, the results from their FREEDOM-2 study are difficult to interpret and warrant further analysis. The company's target price has been lowered, and they may face challenges in gaining regulatory approval without certain features in their product label.

PepGen Inc (PEPG) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Strong Buy based on their latest research and market trends.

According to 6 analysts, PepGen Inc (PEPG) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.